Le Lézard
Classified in: Health
Subjects: PER, SHM

Medical Facilities Corporation Announces Results of 2024 Annual Meeting of Shareholders


TORONTO, May 9, 2024 /CNW/ - Medical Facilities Corporation (TSX: DR) ("Medical Facilities", "MFC" or the "Corporation") announced that the nominees listed in the management information circular for the 2024 Annual Meeting of Shareholders (the "Meeting") held on May 9, 2024 via online webcast were elected as directors of the Corporation.

Detailed results of the votes by proxy and ballot for the election of directors are set out below.

Nominee

Votes
For

% of Votes
For

Votes
Withheld

% of Votes
Withheld

Yanick Blanchard

6,600,999

99.32 %

45,420

0.68 %

Erin S. Enright

6,606,241

99.40 %

40,178

0.60 %

Michael V. Gisser

6,283,088

94.53 %

363,331

5.47 %

Jason P. Redman

6,595,290

99.23 %

51,129

0.77 %

Reza Shahim

6,586,898

99.10 %

59,521

0.90 %

Adina G. Storch

6,597,863

99.27 %

48,556

0.73 %

At the Meeting, the shareholders of the Corporation also approved the appointment of Raymond Chabot Grant Thornton LLP as auditors of the Corporation and authorized the board of directors of the Corporation to fix their remuneration, with 99.63% of the votes in favour.

About Medical Facilities Corporation

Medical Facilities, in partnership with physicians, owns a portfolio of highly rated, high-quality surgical facilities in the United States. MFC's ownership includes controlling interest in four specialty surgical hospitals located in Arkansas, Oklahoma, and South Dakota, and an ambulatory surgery center ("ASC") located in California. The specialty surgical hospitals perform scheduled surgical, imaging, diagnostic and other procedures, including primary and urgent care, and derive their revenue from the fees charged for the use of their facilities. The ASC specializes in outpatient surgical procedures, with patient stays of less than 24 hours. For more information, please visit www.medicalfacilitiescorp.ca.

Caution concerning forward-looking statements

Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties.  Some forward-looking statements may be identified by words like "may", "will", "anticipate", "estimate", "expect", "intend", or "continue" or the negative thereof or similar variations. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in Medical Facilities' filings with Canadian securities regulatory authorities such as legislative or regulatory developments, intensifying competition, technological change and general economic conditions. All forward-looking statements presented herein should be considered in conjunction with such filings. Medical Facilities does not undertake to update any forward-looking statements; such statements speak only as of the date made.

SOURCE Medical Facilities Corporation


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: